Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,405 | -12,423 | -7,621 | -4,694 | -3,415 |
| Depreciation Amortization | 7,484 | 5,626 | 3,722 | 1,851 | 7,278 |
| Income taxes - deferred | 363 | -361 | 407 | 178 | 336 |
| Accounts receivable | 974 | 3,303 | 3,458 | 704 | 810 |
| Accounts payable and accrued liabilities | -1,785 | -283 | -269 | 2,039 | -523 |
| Other Working Capital | 65 | 658 | 130 | 1,708 | 4,600 |
| Other Operating Activity | 6,744 | 3,195 | 730 | -383 | 4,942 |
| Operating Cash Flow | $1,440 | $-285 | $557 | $1,403 | $14,028 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,919 | 1,919 | 1,919 | 495 | N/A |
| PPE Investments | -2,644 | -2,343 | -1,463 | -645 | -1,276 |
| Purchase Sale Intangibles | -619 | -454 | -223 | -75 | -523 |
| Other Investing Activity | -619 | -454 | -223 | -75 | -523 |
| Investing Cash Flow | $-1,344 | $-878 | $233 | $-225 | $-1,799 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 8,800 | 8,800 | 5,550 | 2,500 | 4,500 |
| Debt Repayment | -8,573 | -2,550 | -6,573 | -3,523 | -15,041 |
| Common Stock Issued | 380 | 219 | 204 | 15 | 930 |
| Other Financing Activity | -738 | -5,243 | -59 | -47 | -2,523 |
| Financing Cash Flow | $-131 | $1,226 | $-878 | $-1,055 | $-12,134 |
| Exchange Rate Effect | -140 | 223 | -147 | -151 | -320 |
| Beginning Cash Position | 4,283 | 4,283 | 4,283 | 4,283 | 4,508 |
| End Cash Position | 4,108 | 4,569 | 4,048 | 4,255 | 4,283 |
| Net Cash Flow | $-175 | $286 | $-235 | $-28 | $-225 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,440 | -285 | 557 | 1,403 | 14,028 |
| Capital Expenditure | -2,644 | -2,343 | -1,463 | -645 | -1,788 |
| Free Cash Flow | -1,204 | -2,628 | -906 | 758 | 12,240 |